Text Size   +  + +

Monoclonal (mAbs) antibodies are the latest weapons being tested in the war on Cancer.

The results of tests on standalone mAb protocols for long term remission have some promise, however when combined with a specific immune enhancement protocol the results appear to drastically improve.

In preclinical trials, when mAb protocols were combined with an immune enhancement protocol which utilized a yeast derived immunomodulator, called whole glucan particulate, long term remissions rose to 80%. Whole glucan particulate Beta 1, 3-D Glucan is not a treatment for cancer or any other disease. It is an immunomodulator that has been shown to support immune system function.

"The data suggests that the therapeutic efficacy of certain complement-activating monoclonal antibodies, like Herceptin, Rituxan and Erbitux, could be significantly enhanced if they were combined with NSG," said Gordon D. Ross, Ph.D., Director of the Tumor Immunobiology Program at the James Graham Brown Cancer Center located at the University of Louisville and the senior author of the paper.

In a series of preclinical studies, a therapeutic combination of a patented, soluble yeast beta glucan called NSG and monoclonal antibodies significantly enhanced both tumor regression and long-term survival as compared with monoclonal antibody therapy alone. In the breast cancer model, 40 percent of the mice receiving the combined therapy survived long-term and tumor-free, compared with no survivors among mice treated with the monoclonal antibody or NSG alone. Similarly, in a liver cancer model the combined therapy extended survival and increased long-term survivorship by 25 percent.

Cancer Research publishes significant, original studies in all areas of basic, clinical, translational, epidemiological, and prevention research devoted to the study of cancer and cancer-related biomedical sciences. It is considered the premier research journal on cancer research by the medical profession. http://cancerres.aacrjournals.org

Independent testing has shown whole glucan particulate to be safe and non-toxic and able to enhance immune system function. Whole glucan particulate Beta 1, 3-D Glucan is being studied at over 10 universities and 3 government agencies. These tests are being conducted on;

  • Cancer (breast, colon, lymphoma, and leukemia)

  • Radiation Protection (cancer therapy, nuclear accident, terrorism, and war)

  • Infectious Disease (bacterial, antibiotic-resistant, fungal, and viral infections)

  • General Immune Enhancement

To download these peer reviewed groundbreaking studies for FREE please enter your first and last name as well as your e-mail address below (you can cancel at any time). Upon submission you will be given instant download access to;

  1. Official Report in PDF format titled "Complement function in mAb(monoclonal antibody)-mediated cancer immunotherapy published" by TRENDS in Immunology.

  2. Official Report in PDF format titled "B-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy..." by CANCER RESEARCH.

  3. Educational e-mail series on the latest cancer and health breakthroughs. 7 in all, spaced 2 to 3 days apart (you can cancel at any time).

  4. daily newsletter of articles gathered around the globe on health related issues (you can cancel at any time).

  5. E-Mail your questions to one of the most respected names in Beta 1, 3-D glucan research. He will personally respond to your inquires (it may take 2 to 7 days to respond, he is very busy).

PLEASE NOTE: Your e-mail address is never rented, traded or sold. Hotmail maybe rejected. Click here to review information to ensure your receive your download instructions.